Smith + Nephew Plc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/30/2026)
| Balance Sheet | Total Assets | 10,457,000,000.00 | ROE | 50.58 % |
| Balance Sheet | Total Equity | 5,289,000,000.00 | ROA | 6.10 % |
| Cashflow | Capital Expenditures | -442,630,000.00 | P/FCF | 13.81 |
| Cashflow | Free Cash Flow | 870,950,016.00 | – | – |
| Cashflow | Operating Cash Flow | 1,313,580,000.00 | P/CF | 9.06 |
| Income | Earnings per Share (diluted) | 0.72 | Div. Yield | 2.93 % |
| Income | Net Income | 625,000,000.00 | P/E | 18.26 |
| Income | Shares Outstanding | 872,893,000.00 | P/B | 2.20 |
| Income | Total Revenue | 6,301,090,000.00 | P/S | 1.85 |
Ratios calculated on: 10/13/2026
Company Description
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.smith-nephew.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more